A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...

Some of the key updates include the utilization of GLP-1 medications and an emphasis on prevention of stroke in women. Sadiya Khan, MD, a cardiologist at Chicago-based Northwestern Medicine's Bluhm ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite.

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

In a modular PMA application, the FDA allows applicants to submit discrete sections of the application for review to improve the efficiency ... States that has been created by the availability of ...

Metsera has raised over $500 million to date. Highly competitive, clinical-stage portfolio accelerating Phase 2 trials of ultra-long acting, fully-biased injectable GLP-1 RA underway Metsera recently ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

The discovery could lead to a new treatment for millions of people with obesity and type 2 diabetes who do not respond well to current treatments.